Last reviewed · How we verify
Reduced noradrenaline use
Reduced noradrenaline use refers to a clinical practice or protocol aimed at minimizing the administration of noradrenaline (norepinephrine) in patient care.
Reduced noradrenaline use refers to a clinical practice or protocol aimed at minimizing the administration of noradrenaline (norepinephrine) in patient care. Used for Septic shock or other conditions requiring vasopressor support in intensive care.
At a glance
| Generic name | Reduced noradrenaline use |
|---|---|
| Sponsor | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
| Modality | Small molecule |
| Therapeutic area | Critical Care / Intensive Care Medicine |
| Phase | FDA-approved |
Mechanism of action
This appears to be a clinical intervention or guideline rather than a traditional pharmaceutical drug. It likely involves strategies to reduce dependence on noradrenaline infusions in critical care settings, potentially through alternative vasopressor agents, improved fluid management, or other hemodynamic optimization techniques. The marketed status suggests it may be a clinical protocol or care bundle developed by AMC-UvA.
Approved indications
- Septic shock or other conditions requiring vasopressor support in intensive care
Common side effects
Key clinical trials
- Clinical Outcome and Cost-effectiveness of Reduced Noradrenaline by Using a Lower Blood Pressure Target in Patients With Cardiogenic Shock From Acute Myocardial Infarction (PHASE4)
- Hand Perfusion and Pulse Oximetry Performance
- Norepinephrine and Vasopressin for Rescue Versus Early Vasopressin for Vasopressor Dependent Sepsis (PHASE3)
- Noradrenaline Versus Standard Blood Pressure Management for Perioperative Hypotension in Non-cardiac Surgery (PHASE3)
- Effect of VExUS Ultrasound Protocol (Venous Excess Ultrasound) on Perioperative Fluid Management, on the Incidence of Postoperative Pulmonary Complications and Postoperative Acute Kidney Injury in Patients Undergoing Thoracic Surgery (NA)
- Effect of Perioperative Dexmedetomidine on Chronic Post-Surgical Pain (PHASE4)
- Methadone to Treat Painful Chemotherapy Induced Peripheral Neuropathy (PHASE2, PHASE3)
- Neuroregulators for the Treatment of Diseases Associated With Esophageal-brain-gut Axis Communication Abnormalities. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: